Leukemia Treatment Could Involve Drugs That Block DNA Repair Defects
the Cancer Therapy Advisor take:
According to a new study published in the journal Cell Reports at the National University of Singapore (NUS) in Singapore, Singapore, researchers have discovered a drug that may be useful for the treatment of leukemia and other cancers in which cancer cells have DNA repair defects.
The drug, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with standard chemotherapy could be more effective at treating leukemia than chemotherapy alone. In addition, the researchers found that the inhibition of Runt-related transcription factor (RUNX) genes causes DNA repair defects and promotes the development and growth of leukemia and other cancers.
RUNX genes are often inactivated in leukemia and other cancers. Specifically, RUNX1 is frequently mutated in leukemia and RUNX3 is linked to the development of the disease. According to Motomi Osato, MD, PhD, senior principal investigator from the Cancer Science Institute of Singapore at the NUS, PARP inhibitors have been around for a while, but this study demonstrates their effect on leukemia and other cancers.
The team is also conducting a preclinical study with PARP inhibitors to test drug efficacy. There are currently no PARP inhibitors approved by the U.S. Food and Drug Administration, but there are some undergoing clinical trials.
A drug originally designed for killing cancer cells could potentially be used to treat leukaemia.
DNA Damage Persistent DNA damage, visualized by gammaH2AX staining (red dots), in hematopoietic stem cells could lead to leukemia. Credit: National University of Singapore The new study suggests that treatment with poly (ADP-ribose) polymerase (PARP) inhibitors, together with standard chemotherapy drugs, could be more effective in combating leukaemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia